Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

Status: Recruiting
Location: See location...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• Acute subarachnoid hemorrhage

• Age greater than 18 years

• Secured aneurysm

• Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision

• maker

• Patient or surrogate decision maker is available to consent

Locations
United States
California
UC Davis Medical Center
RECRUITING
Sacramento
Contact Information
Primary
Janice Wang-Polagruto, PhD, CCRP
jfwang@ucdavis.edu
916-551-3244
Backup
Ryan Martin, MD
rymartin@ucdavis.edu
916-734-4300
Time Frame
Start Date: 2024-10-17
Estimated Completion Date: 2026-10
Participants
Target number of participants: 40
Treatments
No_intervention: Standard of Care Medications for Headache
Control arm participants will receive standard of care medications, as defined in a headache protocol, to treat subarachnoid associated headache.
Experimental: Transnasal SPG Block and Standard of Care Medications
Intervention arm participants will receive standard of care medications, as defined in a headache protocol, with the addition of transnasal SPG blocks when a predefined threshold is met per the study protocol.
Sponsors
Collaborators: Agnes Marshall Walker Foundation
Leads: University of California, Davis

This content was sourced from clinicaltrials.gov